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This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).SUMMARYTeratoma formation is the gold standard assay for testing the capacity of human pluripotent stem cells to differentiate into all embryonic
germ layers. Although widely used, little effort has been made to transform this qualitative assay into a quantitative one. Using gene
expression data from a wide variety of cells, we created a scorecard representing tissues from all germ layers and extraembryonic tissues.
TeratoScore, an online, open-source platform based on this scorecard, distinguishes pluripotent stem cell-derived teratomas frommalig-
nant tumors, translating cell potency into a quantitative measure (http://benvenisty.huji.ac.il/teratoscore.php). The teratomas used for
the algorithm also allowed us to examine gene expression differences between tumors with a diploid karyotype and those initiated by
aneuploid cells. Chromosomally aberrant teratomas show a significantly different gene expression signature from that of teratomas orig-
inating from diploid cells, particularly in central nervous system-specific genes, congruent with human chromosomal syndromes.INTRODUCTION
Pluripotent stem cells (PSCs) are defined by their ability for
self-renewal and the capacity to differentiate into cells of
the three embryonic germ layers: ectoderm, endoderm,
and mesoderm (Thomson et al., 1998). These traits turn
human PSCs (hPSCs) into a promising disease-modeling
platform and a unique resource in regenerative medicine.
PSC differentiation capacity, or cell potency, can be evalu-
ated using several strategies. The gold standard assay to
assess the pluripotency of mouse cells is injecting them
into blastocysts, generating chimeric mice with germline
transmission. As for hPSCs, several alternatives exist. One
suggested approach (named PluriTest) is to analyze the
expression profile of the undifferentiated cells and deduce
their pluripotency based on similarities to known pluripo-
tent cells (Mu¨ller et al., 2011).While this approach is prom-
ising, it does not validate a cell capacity to differentiate
toward all lineages. Furthermore, this approach ignores
the possibility that mutations in tissue master regulators
(not analyzed in the assay) will affect the potency of the
cells to differentiate. Numerous in vitro differentiation
protocols have been published, enabling direct differentia-
tion toward cells from all three germ layers. However, this
strategy is seldom used, as it is highly expensive, time
consuming, and complicated. Furthermore, there is no
standard set of direct differentiation protocols sufficient
to determine cell potency (Mu¨ller et al., 2012). In contrast,
in vitro spontaneous differentiation into embryoid bodies
(EBs) is a commonly used method to assess hPSC differen-
tiation capability (Itskovitz-Eldor et al., 2000). AlthoughSteefforts have been made to standardize EB formation and
analyze the differentiation capacity into the different
germ layers, a commonly accepted method has yet to
emerge (Mu¨ller et al., 2012).
Teratoma formation is currently the most abundant
technique used to evaluate hPSC potency. In this assay,
undifferentiated hPSCs are injected into an immune-defi-
cient mouse, forming a heterogeneous tumor composed
of terminally differentiated cells from all germ layers. The
tumors are then sectioned and stained using H&E and eval-
uated by an experienced histologist providing qualitative
examples for differentiation toward each lineage. Sections
can also be stained with antibodies against tissue-specific
markers, providing a more direct qualitative approach.
Almost no effort has been made to quantitatively mea-
sure teratoma cell composition (Mu¨ller et al., 2010),
although it might be highly indicative of the initiating
cell potency and variation. Gene expression data from
teratomas can assess their composition and enable com-
parison of tumors originating from different PSC lines.
However, this kind of analysis and quantitative evaluation
had been so far halted by the lack of publicly published
expression data.
Using teratoma gene expression data initiated from
various hPSC lines, we have developed a method to assess
teratoma tissue and lineage composition, hence evaluating
the initiating cell’s potency. The TeratoScore algorithmuses
in vivo expressionprofiles to calculate andprovide each cell
line with a quantitative measure for pluripotency. Further
comparison between the expression profiles of teratomas
with a normal karyotype and ones with chromosomalm Cell Reports j Vol. 4 j 967–974 j June 9, 2015 j ª2015 The Authors 967
aberrations revealed an abnormal tissue-enriched gene ex-
pression, suggesting that they can aid in disease modeling.RESULTS
In order to evaluate cell composition of hPSC-derived
teratomas, we have analyzed teratomas from 12 different
cell lines (Table S1). Five of the teratomas were generated
from diploid hPSCs. Another five were fromhPSCs with tri-
somy of chromosome 12, and four teratomas were initiated
from hPSCs with trisomy of chromosome 21. Teratomas
were subjected to serial sectioning and H&E staining in or-
der to validate the representation of all three germ layers as
previously shown (Ben-David et al., 2014; Biancotti et al.,
2010; Chin et al., 2009; Lavon et al., 2008; Narwani et al.,
2010). In many histological analyses, structures from all
three embryonic germ layers were found in the same sec-
tion, supporting the notion that different cell types exist
in close proximity in the teratomas (Figure S1). RNA from
different areas of the teratomas was extracted and analyzed
by Affymetrix Human Genome U133 Plus 2.0.
Our aim was to quantitatively analyze cell and lineage
differentiation of the teratomas derived from the hPSCs,
as an indicator for the cells’ potency. An algorithm assess-
ing cell-specific differentiation of PSCs named CellNet
was recently published by Cahan et al. (2014). While
CellNet algorithm is extremely useful when dealing with
a homogenous population of differentiated cells, when
tested by us to examine the differentiation of teratomas,
it has proven limited in assessing the complexity of
hPSC-derived tumors (Figure S2). Although all three germ
layer structures were histologically found in the teratomas
(Figure S1), CellNet showed some similarity to undifferen-
tiated ESCs by no clear enrichment of any specific tissues
(Figure S2A). This was not the case when measuring
homogenous tumors, such as hepatocellular carcinoma,
where CellNet correctly identified the tumor composition.
A more careful analysis of CellNet’s results revealed that
while some tissues, such as liver, were slightly enriched
in the teratomas, the heterogeneous tumors still provided
similar scores to the undifferentiated cells in most
measured tissues (Figure S2B). These results encouraged
us to develop a new platform to assess teratoma composi-
tion, reflecting the pluripotent capacity of human stem
cells that initiated them.
Using previously published expression data sets of
26 different tissues and cell types (Table S2), we generated
a list of 100 genes reflecting tissues from all three germ
layers as well as placental genes, reflecting an extraembry-
onic tissue (Table S3). Genes were chosen according
to tissue specificity, lack of expression in pluripotent
cells, and sufficient expression in an initial database of968 Stem Cell Reports j Vol. 4 j 967–974 j June 9, 2015 j ª2015 The Authorkaryotypically normal teratomas (n = 5). An additional
set of ten pluripotent markers was also generated, as a con-
trol for undifferentiated PSCs. Tissue expression specificity
was validated using the Amazonia! online database, which
represents expression profile of over 300 cell and tissue
types (Le Carrour et al., 2010). The scorecard includes genes
specific for the central and peripheral nervous system as
well as skin-specific genes to represent the ectoderm; genes
specific to the joint, heart, skeletal muscle, adipose tissue,
kidney, and bone marrow to represent the mesoderm;
and genes specific to the gut, liver, lung, and pancreas
representing the endoderm. We also included a subset of
placental genes, representing an extraembryonic tissue.
Following the gene list assembly, we looked at their expres-
sion in teratomas compared with undifferentiated hPSCs
and previously published expression data of tumors from
seven different tissues (Figure 1). Teratomas show expres-
sion of all tissues from all germ layers as well as placental
genes. Importantly, the expression of the different lineages
in these tumors was similar. As expected, undifferentiated
hPSCs show little to no expression of the tissue-specific
genes and a high expression of pluripotency markers.
Similarly, tumors originating from different tissues and
composed mainly of a single cell type were successfully de-
tected by the scorecard as expressing their specific tissue
and lineage. Our scorecard showed specific ectoderm line-
age expression for tumors such as medulloblastoma and
basal cell carcinoma, specific mesoderm lineage expression
for tumors such as liposarcoma and acute lymphoblastic
leukemia, specific endoderm lineage expression for tumors
such as hepatocellular carcinoma and colon cancer, and
the extraembryonic tissue expression for choriocarcinoma
(Figure 1). Congruent results were obtained when the
equivalent normal tissues were measured for the same
scorecard (Figure S3).
In order to quantitatively estimate the pluripotency of
the tumor initiating cells, we calculated the mean gene
expression of each lineage and extraembryonic tissue,
multiplied them, and divided by 1,000, producing a single
score. This analysis, termed TeratoScore, essentially esti-
mates the differentiation potency of the tumor initiating
cells—the very goal of teratoma formation. In other words,
TeratoScore validates the potential of cells to differentiate
toward all three germ layers, hence being qualified as
pluripotent cells. Comparing the TeratoScore outcomes of
14 different teratomas with these of tissue-specific tumors
reveals that it can successfully detect the hPSC-derived
tumors (Figure 2), with average grades of 1,186 ± 334
(n = 14) compared with 7.3 ± 2.6 (n = 34) of the cell-specific
tumors and hPSCs. Of 29 tissue-specific tumors, only one
had a grade higher than 50 (colon cancer, TeratoScore value
of 77). In contrast, only 1 teratoma in the 14 examined had
a grade lower than 100, suggesting that an outcome highers
Figure 1. Average Tissue and Lineage Expression in Different
Tumors and hPSCs
Average tissue gene expression was calculated in respect of its
expression values in the original tissue. Lineage expression was
calculated as the mean expression of all genes representing tissues
in that lineage (n = 2 for basal cell carcinoma and choriocarcinoma;
n = 5 for teratomas, medulloblastoma, liposarcoma, acute
lymphoblastic leukemia, hepatocellular carcinoma, and colon
cancer; n = 10 for hPSCs). Error bars represent SE. Teratomas show
expression of all measured tissues and a similar expression of all
lineages, while other tumors show a specific tissue and lineage
expression. hPSCs show little to no expression of all the tissues.
Pluripotent markers are highly expressed in hPSCs and show low to
no expression in all tumors. C/PNV, central or peripheral nervous
system.
Stethan 100 sufficiently implies a pluripotent cell line-derived
tumor. A TeratoScore value lower than 50 thus indicates
a tissue-specific tumor, and a value between 50 and 100
was a borderline indicator of a tumor originated from
pluripotent cells (Figure 2). Teratoma composition analysis
and the unified outcome using TeratoScore are available
using our online resource at http://benvenisty.huji.ac.il/
teratoscore.php by uploading an Affymetrix U133 Plus
2.0 microarray expression CEL file.
As this is the first time a substantial amount of expression
data regarding teratomas is combined, we were interested
in identifying changes between teratomas with a diploid
karyotype and teratomas initiated by aneuploid cells.
We first examined the differences using the gene scorecard
composing the TeratoScore (Figure 3). While some differ-
ences were statistically significant, the overall tissue
and lineage expression between normal and aberrant cell
lines was similar. Teratomas created by hPSCs with a tri-
somy of chromosome 12 show a significant decrease in
adipose tissue and bone marrow-specific gene expression
compared with normal cell teratomas (p < 0.02 and p <
0.05, respectively) and lower kidney-specific gene expres-
sion compared with normal and trisomy 21 teratomas
(p < 0.05 and p < 0.03, respectively). TeratoScore values
calculated using these results were 1,490 ± 580 (n = 5) for
euploid hPSC-derived teratomas, 1,798 ± 825 (n = 4) for
teratomas derived from trisomy 21 hPSC, and 392 ± 117
(n = 5) for trisomy 12-initiated teratomas. Curiously, the
mean TeratoScore value of teratomas derived from trisomy
12 hPSC is significantly lower than that of teratomas
derived from euploid cells (p = 0.05).
A live newborn with full trisomy 12 was never reported,
suggesting that it is embryonic lethal in humans.
However, individuals carrying mosaic tetrasomy of 12p
were reported showing a variety of abnormalities (Segel
et al., 2006). This condition, known as Pallister-Killian
mosaic syndrome, is extremely rare and has a range ofm Cell Reports j Vol. 4 j 967–974 j June 9, 2015 j ª2015 The Authors 969
Figure 2. TeratoScore Grades of Different Tumors and PSCs
TeratoScore grades were calculated as the multiplication of the
mean lineage gene expression of each tumor divided by 1,000.
While teratomas show high and diverse TeratoScore grades (n = 14,
mean = 1,186, SEM = 334), all other tumors and PSCs produce
significantly lower ones (n = 34, mean = 7.3, SEM = 2.6, p < 106).developmental and behavioral outcomes (Kostanecka
et al., 2012). Individuals carrying chromosome 21 trisomy
also show a distinct set of abnormalities alongside intel-
lectual disabilities, a condition known as Down syndrome
(Patterson, 2009). With such an atypical in vivo develop-
ment, we hypothesized that teratomas originating from
cells carrying these mutations will show a more substan-
tial differential gene expression. We suspected that the
lack of significant changes originated from the small
number of examined genes. While our 100-gene platform
is sufficient for the TeratoScore analysis and defining a cell970 Stem Cell Reports j Vol. 4 j 967–974 j June 9, 2015 j ª2015 The Authoras pluripotent, it is not capable of identifying minor
expression changes and tissue distribution between
euploid and aneuploid cells.
We therefore used another more sensitive bioinformatic
strategy, establishing lists of the 200 most expressed
genes in each tissue and looking for the ones most altered
in chromosomally aberrant teratomas (Figure 4). In this
analysis, trisomy 12-derived teratomas show a significant
number of upregulated genes enriched for joint, spinal
cord, brain, and fetal brain (p < 0.001) and a significant
number of downregulated genes enriched for skeletal
muscle, lung, small intestine, colon, fetal liver, and liver
(p < 0.001) compared with normal karyotype teratomas.
This wide set of gene expression alteration might suggest
a pleiotropic effect of trisomy 12 on developmental pat-
terns, contributing to its embryonic lethality. In contrast,
teratomas initiated from cells with trisomy 21 show a
more modest distortion of gene expression with a signif-
icant number of upregulated genes enriched for brain,
fetal brain, and spinal cord (p < 0.001), as well as for joint,
and a significant number of downregulated genes for
skeletal muscle only compared with normal karyotype
teratomas. The upregulation in brain genes in these tera-
tomas is compatible with the neural phenotypes (such
as mental impairment) observed in Down syndrome
patients.DISCUSSION
Teratoma formation is the most abundant method to
demonstrate hPSC differentiation capacity and a critical
step when defining its potency (Mu¨ller et al., 2010).
TeratoScore transforms this qualitative obligatory mile-
stone into a quantitative tool. Although alternatives have
been suggested to replace teratoma formation, they all
suffer from imperfections. The computational method
PluriTest has shown promising results identifying PSCs
and differentiating them from cancer stem cells and cells
that have underwent differentiation (Mu¨ller et al., 2011).
While this method appears simpler than in vivo or
in vitro differentiations, it can only determine a cell resem-
blance to PSCs in their undifferentiated state. The unique-
ness of PSCs, however, is in their ability to transform from
the pluripotent state to terminally differentiated cell types.
These differentiation processes require master regulators
that are not expressed in PSCs. A mutation in one of these
genes will not be exposed using PluriTest, claiming that a
cell is pluripotent even though it cannot differentiate to-
ward all germ layers. Differentiation per se can be evaluated
using directed and spontaneous in vitro protocols. Directed
differentiation protocols toward many cell types and
tissues have been published, ranging from neurons tos
Figure 3. Average Tissue and Lineage Expression in WT and Chromosomally Aberrant Teratomas
Average gene expression was calculated in respect of its expression values in the original tissue. Lineage expression was calculated as
the mean expression of all genes representing tissues in that lineage (*p < 0.05). WT (n = 5) and chromosomally aberrant teratomas
(trisomy 12, n = 5; trisomy 21, n = 4) show a similar tissue and lineage expression, with exception for significantly lower expression
of genes specific for kidney, adipose tissue, and bone marrow in teratomas with trisomy of chromosome 12 compared with WT. Error bars
represent SE.pancreatic progenitors (reviewed in Schuldiner and Benve-
nisty, 2003; Tabar and Studer, 2014). Each protocol requires
a set of specific factors and environment, presenting expen-
sive and complex challenges to assess cell potency. Further-
more, there is no agreed-upon assembly of protocols which
successful utilization is sufficient in determining cells’ plu-
ripotency. In contrast, spontaneous differentiation is
widely used and relatively simple to perform. EB formation
has been suggested as a good replacement for teratoma
formation. However, EBs do not always show complex
differentiated structures and usually encapsulate a core of
undifferentiated cells. When compared with teratomas,
EBs show a lesser extant of mature tissue differentiation
(Ozolek and Castro, 2011)—a difference that might pro-
vide a limited estimation of the differentiation capabilities.
Teratoma formation enables differentiation to a wide vari-
ety of cells and tissues, presenting mature and complex
structures. Although it is far from being a perfect assay,
teratoma formation is still the best evaluator of pluripotent
assessment.
Using expression data from teratomas, we were able to
identify a large variety of differentiated tissues withinStethem. This allowed us to analyze a repertoire of differen-
tiated cell types in each embryonic germ layer. Teratomas
initiated from PSCs express characteristic genes of all
analyzed tissues and a similar expression of all lineages.
Other tumors are typically composed of uniform and ho-
mogenous tissues, as seen by our 100-gene scorecard. We
show that tumors originating from all lineages as well as
from extraembryonic tissues express the respective genes
in an exclusive manner. Weighing this expression creates
a score that successfully separates PSC-derived mature tu-
mors from tumors originating from other cell types.
While this separation is evident, it is unclear why some
teratomas provide a much higher grade in the TeratoScore
analysis. We were not able to find a common ground for
high or low scores, looking at karyotype integrity or ge-
netic identity. In our study, we have analyzed two sets
of different teratomas generated from the same cell types
(CSES22 and CSES45; see Table S1). The TeratoScore of
both pairs of teratomas was higher than 100, affirming
the cell lines’ pluripotency, but the numbers were some-
what different (160 and 315 for CSES22-initiated tumors
and 234 and 429 CSES45-initiated tumors). Examining am Cell Reports j Vol. 4 j 967–974 j June 9, 2015 j ª2015 The Authors 971
Figure 4. Tissue Classification of Genes Expressed Differently between WT and Aberrant Teratomas
Number of genes differentially expressed in chromosomally aberrant teratomas compared with teratomas initiated from diploid cells. Gene
were considered differentially expressed when changed over 2-fold compared with control (*p < 0.001). Teratomas from cells carrying
trisomy of chromosome 12 (T12, n = 5) showed a significant number of upregulated genes enriched for brain, fetal brain, spinal cord, and
joint as well as downregulated genes enriched for liver and fetal liver, colon, small intestine, lung, and skeletal muscle compared with WT
teratomas (n = 5). In contrast, teratomas from cells carrying trisomy of chromosome 21 (T21, n = 4) showed significant number of
downregulated genes specific for skeletal muscle only, with a significant number of upregulated genes enriched for brain, fetal brain,
spinal cord, and joint.much larger teratoma sample from various sources and
passages, including partially reprogrammed cells, might
aid in identifying a biological origin for TeratoScore per-
formance variation. It is possible that some of the vari-
ance originates from TeratoScore’s limited sensitivity.
Although we show that a 100-gene scorecard is enough
to discover the existence or absence of tissues and lineage,
it is insufficient in identifying possible lineage differenti-
ation biases that might affect the TeratoScore outcome.
This is also true for the measurement of pluripotency
markers’ expression. Pluripotent foci were previously
shown to exist in teratomas initiated from trisomy 12 cells
(Ben-David et al., 2014). While a small subset of pluripo-
tent markers could not detect residual undifferentiated
PSCs, analysis of the top 200 genes expressed in hPSCs re-
vealed that 25 of them were upregulated T12 teratomas
compared with WT teratomas (p < 0.06, following Bonfer-972 Stem Cell Reports j Vol. 4 j 967–974 j June 9, 2015 j ª2015 The Authorroni correction for multiple testing) compared with only 5
in T21 teratomas (p < 0.8).
Several studies have analyzed the differentiation pro-
pensity of hPSCs in vitro, suggesting that different cell
lines have differentiation bias, resulting in unequal ability
to differentiate toward specific cell types (Bock et al.,
2011; Boulting et al., 2011; Osafune et al., 2008).
A method to evaluate these biases has been proposed
(Bock et al., 2011), and their origins have been suggested
to be both genetic and epigenetic (reviewed in Cahan and
Daley, 2013). Furthermore, the International Stem Cell
Initiative (ISCI) (Andrews et al., 2005) is currently con-
ducting a large-scale study to compare different methods
to analyze the pluripotency of human stem cells. Our
aim in generating TeratoScore was to give a quantitative
measure to differentiation of PSCs in vivo as a way to eval-
uate the pluripotency of the cells. Teratomas have longs
been argued to be an intriguing developmental model;
however, the extent of their resemblance to typical devel-
opment is under debate (Ozolek and Castro, 2011). Using
karyotypically abnormal cells, we were able to show signif-
icant changes in tissue-enriched gene expression. Although
these changes were not very significant in the 100-gene
scorecard made to identify pluripotent origins, they were
highly significant when looking at the top 200 genes ex-
pressed in each tissue. Additional copies of chromosomes
12 or 21 caused a substantial increase in expression of genes
related to the CNS. This upregulation may indicate these
aneuploidies influence in vivo, for it is known that
both conditions cause substantial intellectual disabilities
(Chapman and Hesketh, 2000; Segel et al., 2006). Further-
more, case studies have reported joint andmusclemalfunc-
tion in patients with Pallister-Killian mosaic syndrome
(Speleman et al., 1991)—another significant trait in our
analysis. It is important to note that we could not find a
report of patients bearing a complete trisomy of chromo-
some 12. We can cautiously assume that this aberration is
lethal—perhaps due to extant of developmental abnormal-
ities implied in our analysis. In contrast, trisomy 21 seems
to cause a significant downregulation in skeletal muscle-
specific genes only—perhaps correlating with the success-
ful birth of Down syndrome patients and their typical
muscle hypotonia (Cisterna et al., 2013).
It is therefore still unclear howwell a teratoma can reflect
developmental processes in vivo. More data regarding
these and other genetic conditions need to be collected
before reaching final conclusions in this matter. However,
we find these results encouraging in reflecting the impli-
cations chromosomal aberrations have on embryonic
development.
Our scorecard and analysis are currently based on a
specific microarray platform, but they might be applicable
to other methods as well. Our 100-gene scorecard can be
measured using a standard quantitative real-time PCR
platform, generating a TaqMan low-density array (TLDA).
As RNA sequencing is becoming more common and less
expensive, it will also allow a reevaluation of our scorecard
and TeratoScore analysis. This might enable a more elabo-
rated analysis of teratomas, alongside additional biological
material and data.
Our algorithm provides a fast and quantitative evalua-
tion of cell potency. As teratomas are a reliable test for
cell differentiation capacity, it is crucial to use this type
of quantitative tools to evaluate and compare them.
TeratoScore provides an estimation of tissue expression
and lineage distribution, as well as a grade determining
pluripotency. We show that teratomas originating from
karyotypically aberrant cells present an aberrant gene
expression, indicating that they might serve disease
research and modeling.SteEXPERIMENTAL PROCEDURES
Cell Culture
hPSCs were cultured and karyotyped using standard conditions as
previously described (Ben-David et al., 2014). See also Supple-
mental Experimental Procedures.
Tumor Formation and Analysis
Teratomas derived from hPSCs were generated as previously
described (Ben-David et al., 2014). Half of the tumor pieces were
mixed together and taken for RNA extraction, while the rest were
saved for H&E staining, carried out as previously described (Kopper
et al., 2010). See also Supplemental Experimental Procedures.
All experimental procedures in animals were in accordance with
institutional guidelines.
Microarray Analysis
Microarray data of the various body tissues, hPSC, and previously
published teratomas and tumors were downloaded from the GEO
database (Table S2). An expression ratio was calculated between
each tissue and the average of all other body tissues, indicating
tissue specificity. Scorecard genes for each tissue were chosen by
having a high tissue specificity (over 3-fold) and by being ex-
pressed in teratoma but not in hPSCs. Average expression for
each lineage was calculated as the mean expression of all genes
representing that lineage. TeratoScore grades were calculated as
the multiplication of these means and dividing this product
by 103. Top-200 tissue-enriched genes were chosen as the top
unique genes in the tissue/body ratio mentioned above. Statistical
calculations and figures were made in R programming language
(http://www.r-project.org). See also Supplemental Experimental
Procedures.
ACCESSION NUMBERS
TheNCBIGEO accession numbers for themicroarray data reported
in this paper are GEO: GSM1576685 and GSE51455 (Table S1).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental
Procedures, three figures, and four tables and can be found
with this article online at http://dx.doi.org/10.1016/j.stemcr.
2015.05.006.
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